Pfizer has announced that it will spend $164 million to acquire Coley Pharmaceutical Group, a publicly-held biopharmaceutical company specializing in vaccine adjuvant technology and a new class of immunomodulatory drug candidates designed to fight cancers, allergy and asthma disorders, and autoimmune diseases. The acquisition is expected to close early in 2008. “This acquisition is an important component of Pfizer’s vaccine strategy and reflects our commitment to research new and ...